. Enhanced nitric oxide production associated with airway hyporesponsiveness in the absence of IL-10.
airway smooth muscle; exhaled nitric oxide; interleukin-10 knockout mice; methacholine AIRWAY REACTIVITY (AR) to methacholine (MCh) or other cholinergic agents is utilized as a measure of relative contractility of airway smooth muscle in both humans and animals (6, 19) . Assessments of contractility in response to cholinergic stimulation include measurements of FEV 1 in response to MCh in humans (24) and measurement of enhanced pause (Penh), airway resistance, and airway smooth muscle tension development in response to MCh in mice (19) . These measures are affected by the physiological state of the subject and are used to support clinical diagnoses in humans and differentiation of experimental treatments in animals. For example, MCh challenge in humans can establish the presence of elevated AR associated with asthma (10) . Likewise, in animal models, MCh administration can establish links between experimental manipulations of airway inflammation and the consequent airway smooth muscle responses. Furthermore, a reduction in AR to MCh can be indicative of the effectiveness of an exogenous experimental or clinical treatment that reduces airway smooth muscle contractility (1) or the induction of an endogenous agent that reduces contractility (5) .
Interestingly, some prior studies have demonstrated reduced AR in mice in which interleukin (IL)-10 was missing (17) . Conversely, addition of IL-10 has been observed to increase AR in both mouse and rabbit airway smooth muscle (12, 23, 31) . In preliminary studies, we have observed reduced AR in conjunction with increased nitrite levels within bronchoalveolar lavage fluid in IL-10 knockout (IL-10 Ϫ/Ϫ ) mice (B. T. Ameredes, unpublished observations). These findings suggested that the absence of IL-10 was associated with reduced airway smooth muscle contractility, perhaps as a consequence of enhanced production of nitric oxide (NO) as previously observed in airway cells from IL-10 Ϫ/Ϫ mice in vitro (2) . Furthermore, the observations are consistent with prior data showing suppression of nitric oxide synthase (NOS) expression and activity, and consequently reduced NO production, by IL-10 (7, 25) .
Accordingly, we studied AR in IL-10 Ϫ/Ϫ mice and compared them with other strains of mice in which IL-10 was present to determine the link between airway NO production and AR in the presence and absence of IL-10. We hypothesized that a lack of IL-10 would enhance production of NO within the airway and consequently reduce airway smooth muscle contractility. Airway NO production was measured as exhaled NO (E NO ) production in vivo in mice with and without administration of NO inhibitors. AR to MCh was measured both indirectly as Penh and directly as the response of tracheal rings in vitro. The results are consistent with the postulate that a lack of IL-10 results in endogenous NO production that decreases airway smooth muscle contractility.
METHODS
General. Male mice of the C57BL/6 (C57, wild-type), IL-10 Ϫ/Ϫ strain (on a C57BL/6 background) were obtained at 6 wk of age (Jackson Laboratories) and housed under identical conditions in a specific pathogen-free (SPF)/barrier animal facility at the University of Pittsburgh. The IL-10 Ϫ/Ϫ mice were certified as double-knockout IL-10 null-mutants (IL-10 Ϫ/Ϫ ) originating from a strain produced by Kuhn et al. (18) . All mice were allowed to age to 8 -12 wk and were subjected to a series of experimental protocols described below. This maturation window allowed the mice to grow to a sufficient size (18 -25 g ) for experimental manipulation. Because IL-10 Ϫ/Ϫ mice can develop enterocolitis with age (18), they were routinely monitored for evidence of rectal prolapse and failure to gain weight throughout the study. Although housing under SPF conditions significantly attenuates this tendency (18) , mice demonstrating these symptoms were excluded from analysis. All procedures and protocols used in these studies were approved by the University of Pittsburgh Institutional Animal Care and Use Committee, which conforms to guidelines recommended by the National Institutes of Health and the United States Department of Agriculture.
In some experiments, mice were injected with either
, dissolved in normal saline every other day over a 3-day period, to inhibit NO production by all NOS isoforms and by inducible nitric oxide synthase (iNOS), respectively, in vivo. Measurements were made 24 h after the last injection. In other experiments, a subdermal implantable miniosmotic pump (Alzet) was placed in the dorsal cervico-scapular area to deliver recombinant murine (rm)IL-10 (R&D Systems) dissolved in a saline vehicle to achieve doses of 25-125 g ⅐ kg Ϫ1 ⅐ day Ϫ1 ; a cohort group of sham saline vehicle alone was used as the control in this case. Measurements were made 72 h after pump implantation.
E NO production. ENO production in unanesthetized mice was measured by a modification of the technique of Weicker et al. (32) . In brief, mice were placed individually within a closed acrylic chamber with a low volume (ϳ600 ml, Buxco) and allowed to breathe freely for a period of time during which the fractional CO2 content of chamber gas attained 5-5.5%. A small sample of the chamber gas (Յ85 ml) was aspirated (20 s, 250 ml/min) in to a gas analyzer (Logan 2500; Logan Research, Kent, UK) that measured NO (sensitivity ϭ 0.3 ppb, time to 90% of peak response Ͻ0.5 s), using photometric determination of ozone-enhanced chemiluminiscence. The analyzer was calibrated with a certified gas mixture (108 ppb NO) on the morning of each trial and checked periodically with sample gases of known NO concentrations.
In vivo AR measurement. AR was measured in unanesthetized mice as previously described (1) . In brief, mice were placed within smallvolume (ϳ600 ml) Plexiglas chambers that allowed for free movement. Alterations in chamber pressure, as a function of mouse breathing patterns (Buxco), were continuously monitored. The Penh variable was calculated in the conventional way (13) . MCh dissolved in phosphate-buffered saline (pH 7.4) was administered as an aerosol (0 -50 mg/ml) to the mice within the chambers via a DeVilbiss ultrasonic nebulizer connected to an aerosol driver and pump apparatus (Buxco). The administration duration of each MCh concentration was 2 min, followed by a 3-min observation and continued data collection period. The measured response was taken as the highest Penh value achieved during the administration and observation periods.
In vitro AR measurement. Mouse tracheal rings (four to six cartilaginous rings and associated airway smooth muscle; mean wt ϭ 1.7 Ϯ 0.1 and 1.6 Ϯ 0.1 mg for C57 and IL-10 Ϫ/Ϫ mice, respectively) from freshly killed mice (rapid cervical dislocation under Halothane anesthesia; 2% vol/vol, 2 l/min airflow, 5 min) were surgically removed, attached to a wire holder through the lumen of the ring, placed in a 37°C bath (Radnoti) with oxygenated (95% O2/5% CO2) Krebs-Henseleit buffer (in mM: 118 NaCl, 2.8 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, and 11.1 dextrose), and connected via a 4-0 silk suture to tension transducers that were interfaced with an analogdigital board (100-Hz sampling rate) on personal computer-compatible computer running a digital data collection program (BioBench, National Instruments). Rings were stretched to attain 500 -600 mg passive tension, washed with fresh buffer over 30 -60 min, and then exposed to increasing concentrations of KCl (20 -60 mM) for intervals of 10 -15 min/concentration. After reaching maximal tension at the highest KCl concentration, the rings were washed several times with fresh buffer over a 30-min period. A dose-response relationship was obtained with increasing concentrations of MCh (10 Ϫ12 -10 Ϫ6 M) applied for 5 min/concentration. Afterward, atropine was applied to inhibit cholinergic tone and to establish that the prior tension increases observed were MCh dependent. At the end of the experiment, the rings were removed, blotted, and weighed.
Statistics. All statistical analyses were performed with Sigma Stat (SPSS) on a microcomputer. A one-way ANOVA was utilized to assess variability in E NO between groups of mice at an alpha level of 0.05, followed by post hoc testing by Student-Newman Keuls test. Pre-and posttreatment changes in E NO due to NO inhibition were assessed with paired t-tests at an alpha level of 0.05. Changes in ENO due to administration of rmIL-10 were evaluated by one-way ANOVA, followed by application of Dunn's post hoc test, using the sham saline group as control. A repeated-measures ANOVA was utilized to assess variability in both Penh and tension measurements across MCh concentrations and between groups. With acquisition of a significant F statistic (P Ͻ 0.05) by repeated-measures ANOVA, post hoc discreet data analyses between groups within MCh concentrations were performed by Student-Newman-Keuls test, with values of P Ͻ 0.05 considered significant.
RESULTS

AR and baseline E NO . In vivo AR was lower in IL-10
Ϫ/Ϫ mice compared with C57 wild-type controls by up to 37% (Penh with 50 mg/ml MCh ϭ 4.4 vs. 2.9, P Ͻ 0.05) (Fig. 1) . Both strains demonstrated significant AR responses at concentrations of MCh Ͼ10 mg/ml, with the IL-10 Ϫ/Ϫ being lower, or right-shifted. E NO levels were significantly greater in naïve IL-10 Ϫ/Ϫ mice (mean ϭ 12.9 ppb, P Ͻ 0.05) compared with wild-type mice (6.7 ppb, Fig. 2 ).
E NO with inhibition of NOS and IL-10 administration. With inhibition of NOS, E NO was significantly decreased in IL-10 Ϫ/Ϫ mice. Inhibition of NOS using L-NAME resulted in decreased E NO in every individual tested (Fig. 3A) , producing an average drop of 30% (12.3 to 9.0 ppb, P Ͻ 0.05). Inhibition of NOS with L-NIL likewise resulted in decreased E NO in each individual mouse tested (Fig. 3B) , producing an average drop of 68% (9.4 to 2.9 ppb, P Ͻ 0.05). With administration of rmIL-10 to IL-10 Ϫ/Ϫ mice, E NO was decreased in a dosedependent fashion compared with sham saline controls (22.3 ppb), with significant decreases observed at doses of 75 (12.1 ppb, P Ͻ 0.05) and 125 (6.9 ppb, P Ͻ 0.05) g⅐kg Ϫ1 ⅐day Ϫ1 (Fig. 4) . Ϫ/Ϫ mice being hyporesponsive compared with rings from the C57 wild-type mice. With administration of L-NAME, tension development in rings from IL-10 Ϫ/Ϫ mice was significantly increased, to levels similar to rings of C57 wild-type mice [mean ϭ 869 mg with 60 mM KCl, not significant (n.s.)], whereas tension development in C57 wild-type mice given L-NAME was similar to C57 wild-type mice without L-NAME. Tension development in response to MCh was significantly less in tracheal rings from IL-10 Ϫ/Ϫ mice, being hyporesponsive compared with C57 wild-type controls (816 vs. 1,139 mg with 10 Ϫ10 M MCh, P Ͻ 0.05) and was significantly increased with administration of L-NAME (1,030 mg with 10 Ϫ10 M MCh, n.s.) to levels similar to rings of C57 wild-type mice with and without L-NAME administration (Fig. 5B) . Likewise, AR as measured by Penh in vivo was increased with administration of L-NIL in IL-10 Ϫ/Ϫ mice (Fig. 7) . AR with administration of IL-10 and L-NIL. AR, as measured by Penh in vivo, was increased by 36% with administration of rmIL-10 (1.4 to 1.9 with 50 mg/ml MCh, P Ͻ 0.05, Fig. 6 ), suggesting that replacement of IL-10 in IL-10 Ϫ/Ϫ mice resulted in decreased NO that was associated with an increase in AR. Administration of L-NIL to IL-10 Ϫ/Ϫ mice increased AR (Fig.  7) ; however, this increase was not seen in the presence of IL-10 replacement. Ϫ/Ϫ ϪL-NAME decreased vs. C57 ϪL-NAME at same concentration, ϩP Ͻ 0.05 vs. IL-10 Ϫ/Ϫ ϪL-NAME. B: airway tension development in response to increasing concentrations of MCh (statistical symbols as in A).
DISCUSSION
The major findings of this study were 1) a lower level of AR in IL-10 Ϫ/Ϫ mice compared with IL-10-sufficient C57 wildtype mice, 2) a higher level of E NO in IL-10 Ϫ/Ϫ mice compared with C57 wild-type mice, 3) decreased E NO in IL-10 Ϫ/Ϫ mice with inhibition of NOS, 4) increased AR in IL-10 Ϫ/Ϫ mice with inhibition of NOS, 5) decreased E NO with administration of IL-10 to IL-10 Ϫ/Ϫ mice, and 6) increased AR with administration of IL-10 to IL-10 Ϫ/Ϫ mice. These results indicate that a lack of IL-10 is associated with increased airway NO levels, which may predispose the airway toward hyporesponsiveness to cholinergic stimulants. This hyporesponsiveness can be mitigated either with inhibition of NO production using selective inhibitors of NOS activity or through administration of IL-10.
Relationship of NO production and IL-10. The presence of elevated levels of NO within the airways of IL-10 Ϫ/Ϫ mice, compared with IL-10-sufficient mice, is consistent with expectations based the ability of IL-10 to suppress NOS expression (7); e.g., a lack of IL-10 would represent the loss of a natural brake on NOS activity, with consequent increased NO production (Fig. 2) . This initial expected difference was verified by our exhaled gas measurement technique and subsequently was shown to be altered with administration of NOS-specific inhibitors L-NAME and L-NIL (Fig. 3) , similar to findings reported in humans given L-NAME (29) . That the brake on NO production was likely present in the IL-10-sufficient case has been shown previously by Todt et al. (30) , who reported measurable IL-10 protein (0.65-0.75 ng/ml) in the lungs of naïve C57 mice. Furthermore, reconstitution of IL-10 in IL-10 Ϫ/Ϫ mice resulted in a dose-dependent suppression of airway NO production, down to levels similar to the IL-10-sufficient C57 mice (6 -7 ppb, Figs. 2 and 4) . These findings strongly suggest that the normally suppressive effect of IL-10 on NO production is apparent as increased airway NO levels in the absence of IL-10.
It might be suspected that iNOS, or NOS II, would predominate production of NO in the absence of IL-10, which could produce increases in E NO and decreased airway resistance (15) . However, it is difficult to postulate a strong inductive signal in the absence of stimuli like airway inflammation or the presence of pathogens (3, 20, 25) . Our preliminary studies indicated that there is neither measurable difference, nor upregulation of iNOS mRNA or protein, in the lungs of naïve C57 wild-type and IL-10 Ϫ/Ϫ mice (data not shown), suggesting that the increases in airway NO are not due to increased levels of this source enzyme in the absence of IL-10. Therefore, the possibility of increased activity of iNOS not associated with transcriptional or translational regulation remains open. The current results displayed a stronger reduction of E NO with L-NIL compared with L-NAME, which suggests that L-NIL was more effective in suppressing airway NO production, perhaps by iNOS, at the dose level that we used. However, in the absence of an applied experimental stimulus such as airway inflammation, it is also possible that the constitutive/neuronal form, nNOS or NOS I, may dominate (9); furthermore some reports suggest that AR in mice may be linked to the endothelial isoform, eNOS or NOS III (11) . These findings indicate that further studies are necessary to determine the relative effective doses of NOS isoform-specific inhibitors in the absence of IL-10, when regulation of NOS may be altered.
Impact on AR. AR was observed to be lower in IL-10
mice, compared with wild-type C57 mice, as measured both in vivo and in vitro (Figs. 1 and 5 ). Subsequent inhibition of NO with NOS-selective inhibitors increased AR (Figs. 5 and 7), suggesting that NO could be acting as a bronchodilator in the case where IL-10 is absent and consistent with prior studies in humans, in which L-NAME increased AR (29) . This interpretation would be consistent with fact that a lack of IL-10 results in increased airway NO production, as observed in the present study. Further support for this notion was found with reconstitution of IL-10 in the IL-10 Ϫ/Ϫ mice, in which airway NO production was significantly reduced, and was associated with an increase in AR (Figs. 4 and 6) .
The effects of IL-10, and its lack, on AR have been reported to be variable, ranging from being decreased to being unaltered or increased, and appears to be dependent on the model employed (for review, see Ref. 26) . Airway hyporeactivity in the absence of IL-10 has been reported previously, as has the effect of administered IL-10 on restoring AR (12, 17, 23, 27) . Current evidence suggests that IL-10 influences or acts in concert with other factors to increase airway smooth muscle activity (17) , perhaps involving autocrine signaling through IL-5 (12) or regulation of surfactant protein D (28); however, there has been no further consensus beyond these points. An additional point to be noted is that many of the models utilize allergen-driven airway inflammation, and most show either no difference or small differences in AR of naïve IL-10 Ϫ/Ϫ mice compared with IL-10-sufficient C57 counterparts. We have further clarified that there can be measurable hyporesponsiveness in naïve IL-10 Ϫ/Ϫ mice, associated with the production of NO, through a mechanism that may involve reductions in airway smooth muscle contractility in response to MCh.
Although we have developed the notion that NO in the absence of IL-10 may be acting as a bronchodilator through actions in airway smooth muscle that may be similar to its actions in vascular smooth muscle (22) , another potential explanation for NO-associated airway hyporesponsiveness may actually lie in the action of NO on the vasculature of the lung. For example, in rodent experiments, application of positive end-expiratory pressure (PEEP) is commonly used to return MCh-driven lung resistance levels to precholinergic stimulus levels, in part through induction of pulmonary vasodilation and substrate washout, subsequent to vascular compression by PEEP. It is conceivable that the action of NO to promote pulmonary vasodilation could be bronchoprotective in an indirect fashion that does not necessarily require relaxation of airway smooth muscle. In this case, elevated levels of NO in the lung in the absence of IL-10 could result in NO-induced vasodilation and enhanced washout that would manifest as airway hyporesponsiveness in the face of a cholinergic challenge, as we observed. This explanation would be consistent with findings that eNOS is a major source of airway NO and is strongly associated with AR in mice (11) . Further study is necessary to determine whether this mechanism may be a reason for these observations in this and other models of AR. However, the supporting data from our tracheal ring experiments in vitro argue for a more direct effect of NO on airway smooth muscle function, perhaps as a function of constitutive NOS present in the intact epithelium of those preparations.
Critique of methods. We used the measurement of Penh as an index of AR in vivo, because it allowed a rapid noninvasive assessment of AR measurements in large numbers of mice, using inhaled MCh. However, there has been recent controversy as to whether Penh can accurately reflect changes due to bronchoconstriction in mouse models (21) . Although we acknowledge some limitations to the Penh technique, we agree with the assertion by DeLorme and Moss (8) , that the choice of the Penh measurement should be linked to the study objective and the ability to track alterations in AR previously verified by more invasive measures of lung resistance. The latter requirement was fulfilled in the present study by assessment of tension development of airway smooth muscle within tracheal rings, in vitro, and by the prior study of Justice et al. (17) , in which Penh in C57 and IL-10 Ϫ/Ϫ mice was shown to display results consistent with measures of lung resistance in situ and airway smooth muscle tension development in vitro.
Clinical implications. It has been shown that IL-10 production is decreased, and E NO is elevated, in patients with allergic asthma (4, 16) . Those findings are consistent with our present observations of elevated E NO in IL-10 Ϫ/Ϫ mice. However, the alterations in humans occur in asthma with increased AR, a situation that is superficially counterintuitive, as elevated NO production might be expected to decrease AR (15) . However, it is possible that elevated E NO in asthma may reflect increased production of NO as a potential homeostatic bronchoprotective agent (29) . In this context, enhanced NO could act to minimize AR in the face of strong proinflammatory stimuli and subsequent products that increase AR (12, 28) . This may be particularly true in the case of established late-phase allergic asthma, typically characterized by airway inflammation, eosinophilia, elevations in IL-5, and increased AR (5) and could explain the presence of a negative correlation between rising E NO levels and increasing airway hyper-responsiveness (16) . In this regard, the notion can be obtained that AR in allergic asthma might be worse were it not for the protective effects of endogenous NO production. Thus it may be that there are powerful feedback mechanisms associated with increased production of NO in the absence of IL-10 that may help to regulate AR. Further study is necessary to elucidate these potential mechanisms and their influence on AR in setting of reduced IL-10 production.
